AZ antibody cocktail reduces risk of severe COVID by 88%

Thursday, 18. November 2021 09:08

AstraZeneca plc unveiled on Thursday the results of its Phase 3 trial for its coronavirus antibody cocktail AZD7442 which indicates high efficiency when dealing with severe COVID cases or deaths.

The first part of the trial showed that a 600 mg intramuscular (IM) dose of AZD7442 in patients with mild-to-moderate conditions reduces the risk of developing serious conditions or death by 88%.

At the same time, another part, evaluating over the course of six months, showed that a single dose, 300 mg, of the cocktail reduced the risk of patients getting symptoms from the virus by 83%. No new safety risks were found over the course of the trials.

Related Links: AstraZeneca plc
Baha Breaking the News (BBN) / OL